Business Wire

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis

- Primary endpoint reached: safe and well tolerated, no evidence of adverse reactions related to MH002 when administered for 16 weeks - Initial efficacy observed in clinically relevant parameters, ...

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases ...
AOL

Targeted therapy may help treat moderate to severe ulcerative colitis: trial

Ulcerative colitis is a chronic condition characterized by inflammation and ulcers in the colon. Research is ongoing to expand treatment options. A study published in the New England Journal of ...
Becker's ASC

Entyvio improves moderate-to-severe ulcerative colitis, Crohn’s

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
MedPage Today

Etrasimod Shows Promise in Moderate to Severe Ulcerative Colitis

Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis ...
clinicaladvisor.com

American Gastroenterological Association Releases First “Living” Guideline for Moderate-to-Severe Ulcerative Colitis

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Business Wire

Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology

- Phase 1b study results demonstrate an impact on clinical remission and endoscopic improvement with a favorable safety profile in patients with mild-to-moderate ulcerative colitis- - Detailed ...
Healio

FDA approves Zeposia for moderate-to-severe ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved ...

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
clinicaladvisor.com

Standardized Definition of Mild to Moderate Ulcerative Colitis Needed

ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate, active ...
Pharmabiz

MRM Health receives US FDA IND clearance to initiate phase 2b trial of MH002 in mild-to-moderate ulcerative colitis

MRM Health receives US FDA IND clearance to initiate phase 2b trial of MH002 in mild-to-moderate ulcerative colitis: Ghent, Belgium Saturday, January 10, 2026, 16:00 Hrs [IST] MRM ...

MRM Health NV: MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...